|
|
Exchange: |
American Stock Exchange |
Security
Type: |
Common |
Shares
Out: |
169,410,000 |
Market
Cap: |
97.83(M) |
Last
Volume: |
3,856,623 |
Avg
Vol: |
3,846,095 |
52
Week Range: |
$0.35 - $0.885 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Health Services |
Level
III Sector: |
Medical Instruments & Supplies |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Inovio Pharmaceuticals is a biotechnology company focused on bringing the designed deoxyribonucleic acid (DNA) medicines and vaccines to help protect people from infectious diseases, including COVID-19, and to help treat people with cancer, and conditions associated with human papillomavirus. Co.'s DNA medicines pipeline is comprised of three types of product candidates: prophylactic DNA vaccines, therapeutic DNA immunotherapies, and DNA encoded monoclonal and bispecific antibodies, all of which utilize the two components of Co.'s integrated platform, SynCon® and CELLECTRA®. Co. is evaluating the feasibility of, conducting or planning clinical studies of its DNA medicines.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
0 |
0 |
0 |
37,076 |
Total Sell Value |
$0 |
$0 |
$0 |
$60,923 |
Total People Sold |
0 |
0 |
0 |
3 |
Total Sell Transactions |
0 |
0 |
0 |
5 |
End Date |
2024-03-07 |
2023-12-05 |
2023-06-06 |
2022-06-06 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Collins Morton |
Director |
|
2014-08-21 |
4 |
B |
$10.01 |
$80,090 |
I/I |
8,000 |
36,750 |
2.1 |
- |
|
Collins Morton |
Director |
|
2014-08-20 |
4 |
B |
$9.72 |
$306,958 |
I/I |
31,500 |
32,750 |
2.1 |
- |
|
Collins Morton |
Director |
|
2014-08-20 |
4 |
B |
$9.71 |
$88,433 |
D/D |
9,100 |
173,066 |
2.39 |
- |
|
Kim Jong Joseph |
Chief Executive Officer |
|
2014-08-12 |
4 |
B |
$9.06 |
$2,263,750 |
I/I |
250,000 |
1,750,000 |
2.66 |
- |
|
Sardesai Niranjan |
Chief Operating Officer |
|
2014-08-12 |
4 |
B |
$8.70 |
$22,185 |
D/D |
2,550 |
28,000 |
2.74 |
- |
|
Kim Jong Joseph |
Chief Executive Officer |
|
2014-04-15 |
4 |
B |
$2.25 |
$56,250 |
D/D |
25,000 |
5,965,809 |
2.81 |
- |
|
Collins Morton |
Director |
|
2013-11-13 |
4 |
B |
$1.82 |
$117,422 |
I/I |
64,500 |
75,000 |
2.1 |
- |
|
Collins Morton |
Director |
|
2013-11-13 |
4 |
B |
$1.82 |
$345,895 |
D/D |
190,000 |
655,864 |
2.39 |
- |
|
Bagarazzi Mark |
Chief Medical Officer |
|
2013-04-16 |
4 |
B |
$0.56 |
$33,540 |
D/D |
60,000 |
60,000 |
2.74 |
- |
|
Kim Jong Joseph |
Chief Executive Officer |
|
2013-04-02 |
4 |
B |
$0.50 |
$45,180 |
D/D |
90,000 |
11,940,809 |
3.23 |
- |
|
Cabrera Angel |
Director |
|
2013-03-22 |
4 |
B |
$0.54 |
$21,592 |
D/D |
40,000 |
115,000 |
2.39 |
- |
|
Sardesai Niranjan |
Chief Operating Officer |
|
2013-03-20 |
4 |
B |
$0.53 |
$13,328 |
D/D |
25,000 |
101,800 |
2.74 |
- |
|
Kim Jong Joseph |
Chief Executive Officer |
|
2013-03-20 |
4 |
B |
$0.53 |
$31,680 |
D/D |
60,000 |
11,850,809 |
3.23 |
- |
|
Collins Morton |
Director |
|
2013-01-15 |
4 |
B |
$0.67 |
$66,940 |
I/I |
100,000 |
50,000 |
2.1 |
- |
|
Kim Jong Joseph |
Chief Executive Officer |
|
2013-01-04 |
4 |
GA |
$0.53 |
$79,485 |
I/I |
150,000 |
134,130 |
|
- |
|
Kim Jong Joseph |
Chief Executive Officer |
|
2013-01-04 |
4 |
GD |
$0.53 |
$79,485 |
D/D |
150,000 |
11,790,809 |
|
- |
|
Marxe Austin W & Greenhouse David M |
10% Owner |
|
2012-12-03 |
4 |
S |
$0.55 |
$13,750 |
I/I |
(25,000) |
3,919,706 |
|
- |
|
Marxe Austin W & Greenhouse David M |
10% Owner |
|
2012-11-30 |
4 |
S |
$0.55 |
$51,040 |
I/I |
(92,800) |
3,944,706 |
|
- |
|
Marxe Austin W & Greenhouse David M |
10% Owner |
|
2012-11-29 |
4 |
S |
$0.54 |
$228,291 |
I/I |
(418,700) |
4,037,506 |
|
- |
|
Marxe Austin W & Greenhouse David M |
10% Owner |
|
2012-11-28 |
4 |
S |
$0.57 |
$54,394 |
I/I |
(96,000) |
4,456,206 |
|
- |
|
Marxe Austin W & Greenhouse David M |
10% Owner |
|
2012-11-27 |
4 |
S |
$0.49 |
$318,370 |
I/I |
(650,000) |
4,552,206 |
|
- |
|
Marxe Austin W & Greenhouse David M |
10% Owner |
|
2012-11-26 |
4 |
S |
$0.47 |
$141,180 |
I/I |
(300,000) |
5,202,206 |
|
- |
|
Marxe Austin W & Greenhouse David M |
10% Owner |
|
2012-11-23 |
4 |
S |
$0.47 |
$58,691 |
I/I |
(123,900) |
5,502,206 |
|
- |
|
Marxe Austin W & Greenhouse David M |
10% Owner |
|
2012-11-21 |
4 |
S |
$0.47 |
$108,744 |
I/I |
(230,000) |
5,626,106 |
|
- |
|
Marxe Austin W & Greenhouse David M |
10% Owner |
|
2012-11-20 |
4 |
S |
$0.47 |
$59,976 |
I/I |
(126,800) |
5,856,106 |
|
- |
|
505 Records found
|
|
Page 16 of 21 |
|
|